Our ambition is to cure cancer
by supplying actinium-225 to the radiopharmaceutical industry
AlfaRim is a deep tech start-up company in the field of medical isotope production. We have developed an innovative process technology for the production of the medical isotope of choice: actinium-225 (Ac-225). We apply a holistic approach in the development of our state-of-the-art radiopharmaceutical facility for the large-scale production of cGMP-grade Ac-225. We excel when it comes to the intricacies of radioisotope production, and our technology will guarantee a continuous supply of Ac-225. This will make us a leading supplier – and your trustworthy partner.
Why we do it
At AlfaRim, we believe in a world where people no longer die from cancer or suffer unnecessarily during their treatment; a world where a cure can be found through the right combination of ingenuity, therapy and medication. Our ambition is to cure cancer.
How we do it
We believe that Targeted Alpha Therapy is the right method for curing cancer. By supplying Ac-225 to the radiopharmaceutical industry, we will
1) allow existing clinical research initiatives on Targeted Alpha Therapy to come into maturity, and
2) pave the way for Targeted Alpha Therapy to become a mainstream therapy for the treatment of many types of cancer.
What we do
Therefore, we will make cGMP-grade, cyclotron-produced Ac-225 available in large quantities for acceptable prices. Straight from our production facility in Delft, the Netherlands, we will offer a worldwide supply of Ac-225 – in predictable quantities and at predictable moments in time.
A multi-disciplined management team with almost 70 years of combined experience in nuclear medicine, applied physics, engineering, finance and management.